Litcius/Paper detail

The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development

Zhengying Zhou, Jinwei Zhu, Muhan Jiang, Lan Sang, Kun Hao, Hua He

2021Pharmaceutics21 citationsDOIOpen Access PDF

Abstract

Human-derived in vitro models can provide high-throughput efficacy and toxicity data without a species gap in drug development. Challenges are still encountered regarding the full utilisation of massive data in clinical settings. The lack of translated methods hinders the reliable prediction of clinical outcomes. Therefore, in this study, in silico models were proposed to tackle these obstacles from in vitro to in vivo translation, and the current major cell culture methods were introduced, such as human-induced pluripotent stem cells (hiPSCs), 3D cells, organoids, and microphysiological systems (MPS). Furthermore, the role and applications of several in silico models were summarised, including the physiologically based pharmacokinetic model (PBPK), pharmacokinetic/pharmacodynamic model (PK/PD), quantitative systems pharmacology model (QSP), and virtual clinical trials. These credible translation cases will provide templates for subsequent in vitro to in vivo translation. We believe that synergising high-quality in vitro data with existing models can better guide drug development and clinical use.

Topics & Concepts

In silicoDrug developmentPhysiologically based pharmacokinetic modellingDrug discoveryComputational biologyIn vivoComputer scienceClinical trialDrugPharmacologyPharmacokineticsBiologyBioinformaticsBiotechnologyGeneBiochemistry3D Printing in Biomedical ResearchPluripotent Stem Cells ResearchCancer Cells and Metastasis